Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018;20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Since 1995, the American Academy of Neurology has provided guidelines for brain death determination, but nationwide adherence to these guidelines has been incomplete.
AMA J Ethics. 2020;22(12):E1027-1032. doi:
10.1001/amajethics.2020.1027.